Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Preliminary Results Yield 43% Overall Response Rates (via RECIST) in the Efficacy Population Data Demonstrate REM-422, the First-in-Class Small Molecule…